探索非编码RNA与结肠直肠癌中的糖解之间的联系
Liang Xu1, Yu Shen2, Chuanqiang Zhang3,4
1Neonatal Department, Suzhou Ninth People's Hospital, Suzhou Ninth Hospital Affiliated to Soochow University, Suzhou, Jiangsu, China.
Journal of cellular and molecular medicine
|February 24, 2025
概括
非编码RNAs (ncRNAs) 通过改变糖解,显著影响结直肠癌 (CRC) 的进展. 了解这些ncRNA通路为CRC诊断和治疗提供了新的途径.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 糖解是一种关键的代谢途径,与结直肠癌 (CRC) 的发展和进展有关.
- 在CRC中经常观察到非编码RNAs (ncRNAs) 的异常表达,包括microRNAs (miRNAs),长非编码RNAs (lncRNAs) 和圆形RNAs (circRNAs).
- 人们越来越认识到ncRNAs在调节癌症关键的细胞过程中的作用,例如扩散,入侵和化学抵抗.
研究的目的:
- 在CRC的背景下,审查和综合目前关于ncRNAs在调节糖解中的作用的研究.
- 阐明通过不同类型的ncRNAs影响CRC细胞中的糖解过程的独特途径.
- 突出ncRNAs作为CRC的治疗标和生物标记物的潜力.
主要方法:
- 文献综述和近期科学出版物的综合.
- 分析研究的分析研究ncRNAs和糖解酶或CRC中的调节者之间的相互作用.
- 检查结直肠瘤细胞中ncRNA介导的糖解调节的分子机制.
主要成果:
- 通过调节糖解,ncRNAs在控制CRC细胞增殖,侵入性,化学抵抗性和免疫逃避方面发挥着重要作用.
- 已经确定了特定的miRNAs,lncRNAs和circRNAs,它们可以促进或抑制CRC中的糖解.
- 这些ncRNA通过多种途径发挥其作用,影响关键的糖解酶和细胞代谢.
结论:
- ncRNAs是结直肠癌中糖解的关键调节者,影响疾病的多种特征.
- 准参与CRC糖解的ncRNA是一种开发新型治疗干预措施的有希望的策略.
- 与糖溶性变化相关的ncRNA具有作为CRC的诊断和预后生物标志物的潜力.
更多相关视频
08:53Real Time Analysis of Metabolic Profile in Ex Vivo Mouse Intestinal Crypt Organoid Cultures
Published on: November 3, 2014
16.2K
10:33Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts
Published on: April 29, 2014
11.0K
相关概念视频
lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Non-LTR Retrotransposons
11.3K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.3K
